Partnerships

Our partnerships are driven by our goals to provide breakthrough technology with rewards and results in a highly competitive timeframe.

Partnerships

Collaborative Development and Licensing Agreements

We apply our proprietary delivery platform technologies and expertise in pharmaceutics, drug delivery and drug manufacture with the goal of minimizing the risk, time and manufacturing cost of bringing the finished product to market.

Some of our product candidates have been partnered under drug development arrangements with third parties which may provide for milestone and success fees, support for internal development costs, coverage of clinical trial costs and royalties or profit sharing on product sales.

Our Services

To meet the expectations of clients who demand the best pharmaceutical technology in the industry, and to ensure that we fulfill the most stringent development timeframes, we continue to develop in-house capabilities in controlled release and abuse deterrent product formulations. These range from pre-formulation studies, design and development right through to regulatory approval.

  • Exclusive Licensing Projects

    Our services include life cycle management for products near or at the end of their patent life, and the enhancement of new chemical entities (NCEs). We continue to develop a wide array of products for exclusive licensing projects and are also seeking to bring late stage products to market.
  • Intelligent Drug Delivery

    In any partnership agreement we bring speed, technology and tenacity; we seek to use our intelligent drug delivery systems to position our products and those of our clients at the forefront of any controlled release market.

Our proven track record

Our robust technology platform

The expertise of industry leaders

Our scientific breakthroughs

Once we have partnered, our purpose is simple:

to provide breakthrough technology with rewards and results in a highly competitive timeframe.

Partner With Us

Licensing Opportunities

  • Life Cycle Management

    We are actively seeking opportunities to license our proprietary drug delivery platforms to owners of patented, branded multiple dose per day products. The natural life cycle of those products can potentially be extended far beyond the expiry of the underlying patents, when ordinarily generic introductions might be expected to cause substantial sales erosion. The development of a proprietary controlled-release formulation, for sale under the banner of the original, established brand, is a sound brand management strategy, which should be considered long before the expiry of the patents.
  • New Chemical Entities

    Our drug delivery technology licensing program is particularly well suited to the requirements of owners of new chemical entities (NCE's) whose short half lives make multiple dosing per day necessary. Our proprietary technologies offer the means to add new dimensions to these products by enabling once a day delivery.
  • Portfolio Products

    Our strength lies in our dynamic product pipeline. Present internal pipeline products, which are available for mid to late stage licensing, include new drugs (NDA's) designed to extend the life of, improve upon or replace existing branded drugs, and bio-equivalents (ANDA's) of successful branded controlled-release drugs. Based upon our track record, the chance of successful development of these products is excellent.

We have a strong track record

in designing and developing controlled-release drug products for our clients. Eight bio-equivalent controlled release products and dosages in the U.S. market today were designed and developed by our scientists (including products that predate Intellipharmaceutics) and have enjoyed strong sales in the demanding U.S. market.

Partner With Us